A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children With Severe Uncontrolled Asthma (HORIZON)
Latest Information Update: 08 Apr 2025
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms HORIZON
- Sponsors AstraZeneca
Most Recent Events
- 02 Nov 2023 Planned End Date changed from 10 Jan 2028 to 31 Dec 2027.
- 02 Nov 2023 Planned primary completion date changed from 3 May 2027 to 23 Apr 2027.
- 08 Sep 2023 New trial record